The forecast for mortality rates from trachea, bronchus, or lung malignant neoplasms among women in the US shows a gradual decline from 28.3 in 2024 to 22.0 in 2028 per 100,000 women. This represents a year-on-year reduction of approximately 5.7% to 6% on average. Prior to this forecast, the rate stood at a higher level in 2023, reflecting ongoing improvements in treatment, prevention, and public health measures. The compound annual growth rate (CAGR) over the forecast period indicates a steady annual decline in mortality.
Future trends to watch include advancements in early detection technologies, shifts in smoking prevalence, and innovations in personalized medicine, all of which could further impact mortality rates. Additionally, healthcare policy changes and their effects on treatment accessibility may influence these outcomes.
